H. Res. 1133 is a simple House resolution that endorses designating November 7 of each year as “Shwachman‑Diamond Syndrome Awareness Day.” The text catalogs clinical features of Shwachman‑Diamond syndrome (SDS), highlights underdiagnosis, and frames greater public awareness as a way to spur support and research.
The resolution is symbolic: it expresses the House’s support for an awareness day and urges promotion of initiatives at national, state, and local levels. It does not authorize funding or create new federal programs, but it does take effect immediately upon adoption.
At a Glance
What It Does
The resolution formally supports establishing an annual awareness day on November 7 and records a series of findings about SDS in its preamble. It contains no appropriations, regulatory mandates, or authority to direct federal agencies; its operative language is expressive rather than prescriptive.
Who It Affects
Direct legal obligations are minimal: the text is a non‑binding expression of Congress. Practically, the day is relevant to rare disease advocacy groups, clinical providers and genetics programs, patient registries, and researchers who may leverage the date for outreach, fundraising, or recruitment.
Why It Matters
Official recognition can concentrate outreach, encourage state and local proclamations, and create recurring opportunities for coordinated communication and fundraising. For professionals, the day functions as a predictable moment to raise clinical awareness, boost diagnostic vigilance, and attract philanthropic and research attention toward SDS.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H. Res. 1133 is a House simple resolution that records a series of “whereas” findings about Shwachman‑Diamond syndrome — a rare, inherited condition affecting bone marrow, the pancreas, and the skeleton — and then states the House’s support for designating November 7 as an annual awareness day.
The operative language is brief: the House “supports the designation,” asks for increased awareness and support, and declares the measure takes effect immediately. There are no programmatic directives or funding authorizations.
The preamble lists clinical hallmarks (bone marrow dysfunction, pancreatic insufficiency, skeletal problems), diagnostic approaches (clinical, laboratory, and genetic testing), and treatment components (pancreatic enzyme replacement, nutritional support, white blood cell stimulants, and regular monitoring). It also emphasizes underdiagnosis and limited research attention, which the sponsors present as the rationale for an awareness day.Because the resolution is symbolic, its practical impact depends on follow‑on activity by stakeholders.
Advocacy organizations can use the annual date to plan campaigns, clinicians and genetic counselors can coordinate educational events, and research groups can align calls for proposals or patient‑registry enrollment drives. State and local governments commonly echo such federal observances with proclamations, which can further publicize screening and care needs.The resolution does not change clinical standards, insurance coverage, or federal grant priorities by itself.
Its value lies in creating a recurring, named touchpoint that interested parties can use to mobilize resources, publicize diagnostic pathways, and press for more research — but any material changes (funding, new programs, or guideline revisions) would require separate legislative or administrative actions.
The Five Things You Need to Know
H. Res. 1133 is a House simple resolution (not a law) that expresses the House’s support for an annual awareness day rather than imposing regulatory or funding mandates.
The resolution names November 7 as the annual Shwachman‑Diamond Syndrome Awareness Day and includes an explicit operative clause stating it takes effect immediately upon adoption.
Sponsors listed on the resolution are Rep. Thomas Kean and Rep. Josh Gottheimer, indicating bipartisan sponsorship at introduction.
The preamble asks for promotion of awareness and research initiatives at national, state, and local levels — it invites coordination but does not allocate funds or direct agencies to act.
The resolution was submitted as H. Res. 1133 and, as typical for House resolutions, was introduced without creating binding obligations for federal agencies or private parties.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Catalogs clinical facts and policy rationale
The preamble collates a range of clinical and epidemiological statements about SDS — inheritance pattern, typical age of onset, pancreatic insufficiency, bone marrow dysfunction, skeletal abnormalities, underdiagnosis, and a claimed reduction in life expectancy. These findings form the sponsors’ factual basis for calling attention to SDS and provide talking points advocacy groups can reuse in communications.
House support for the awareness day
The operative paragraph says the House “supports the designation” of November 7 as Shwachman‑Diamond Syndrome Awareness Day to increase awareness and promote research. Because the language is hortatory, the practical effect depends on actions by external stakeholders — advocacy groups, clinicians, and funders — rather than on new federal authorities or entitlements.
Immediate effect and formalities
The resolution concludes with a short clause stating the act shall take effect immediately. For a simple House resolution this is largely procedural — it clarifies that, if adopted, the designation and any House expressions of support are effective as an official posture from adoption forward, but it does not create administrative directives or funding streams.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals with SDS and their families — gain a recurring, nationally recognized date that advocacy groups and clinicians can use for outreach, education, and fundraising to improve diagnosis and access to multidisciplinary care.
- Rare disease advocacy organizations and registries — receive a predictable platform for awareness campaigns, volunteer recruitment, and donor engagement that can increase visibility and patient enrollment.
- Clinical genetics programs and pediatric hematology/oncology clinics — obtain an externally recognized moment to conduct targeted education for clinicians and to promote testing and monitoring protocols that could reduce underdiagnosis.
- Academic and clinical researchers focused on SDS and related marrow disorders — can use the date for coordinated recruitment to natural history studies, grant‑driven awareness efforts, and partnership building with funders.
- State and local health departments and patient support networks — can adopt proclamations or local events that multiply outreach beyond federal symbolism.
Who Bears the Cost
- House administrative offices and staff — minor logistical and communication costs for drafting, publishing, and any House observances tied to the resolution.
- Advocacy groups and nonprofits — bear the primary expense of turning the awareness day into effective programs (campaigns, events, testing drives) without new federal funding.
- Clinics and professional societies — may face incremental costs if they organize educational events or screenings tied to the awareness day, including staff time and materials.
- Federal agencies and grantmakers — may receive increased inquiries or requests for programs and research support, creating administrative load even though no new funds are authorized.
- Patients and families — could face heightened expectations for immediate improvements in services or funding that the resolution alone cannot deliver, creating potential frustration if follow‑on actions do not materialize.
Key Issues
The Core Tension
The bill pits the low‑cost gains of symbolic recognition — increased visibility, easier fundraising, and an organizing date for stakeholders — against the risk of creating expectations for tangible improvements that the resolution cannot deliver without follow‑on funding or policy changes; raising awareness is straightforward, turning that awareness into sustained research investment and clinical change is not.
The resolution’s central limitation is its symbolic character. An awareness day can raise visibility, but without appropriations or regulatory hooks it does not create new screening programs, research funding, or insurance coverage changes.
That means measurable outcomes (higher diagnosis rates, new trials, improved life expectancy) depend on separate actions by agencies, funders, and Congress.
Operationalizing an awareness day also raises practical questions: who coordinates national messaging, how to measure success, and whether limited advocacy dollars will be reallocated from other rare conditions. The bill’s factual claims (incidence, mortality impact) supply a narrative urgency, but those figures may be contested or updated by clinical researchers; relying on static epidemiologic numbers could mislead planning if registries improve or estimates change.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.